Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisotumab vedotin alone and in combination for recurrent or stage IVB cervical cancer
NL-OMON52957Phase 2Recruiting
- Sponsor
- Genmab
- Start
- Apr 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tisotumab vedotin in Cervical Cancer (CC) (8 arms), sponsored by Genmab. Primary endpoints: Dose-limiting toxicities, Safety and tolerability and 1 more. Started Apr 2020; status: recruiting.
02
Drugs
tisotumab vedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON52957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52957.